Gene therapy trial for RDH12-related eye disease
Part of Eyes & vision clinical trials.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 8 and 45 years old.
- You must have a genetic eye condition caused by changes in the RDH12 gene.
- Your vision in the study eye must be 20/63 or worse on a standard eye chart.
- You cannot have had any eye surgery in the study eye in the last 3 months.
- You must not have had any gene therapy treatments in the past.
- Women who could become pregnant must use effective birth control during the study and for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Hear when a new Inherited Retinal Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.